位置:首页 > 产品库 > C16 Globotriaosylceramide-d9(d18:1/16:0-d9)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
C16 Globotriaosylceramide-d9(d18:1/16:0-d9)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
C16 Globotriaosylceramide-d9(d18:1/16:0-d9)图片
包装:500ug
规格:98%
市场价:10297元
分子量:1033.4

A neuropeptide with diverse biological activities
货号:ajcx21888
CAS:N/A
分子式:C52H88D9NO18
分子量:1033.4
溶解度:
纯度:98%
存储:Store at -20°C
库存:现货

Background:

C16 Globotriaosylceramide-d9(d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 globotriaosylceramide by GC- or LC-MS. C16 Globotriaosylceramide (d18:1/16:0) is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide .1C16 Globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.2It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder.3Plasma levels of C16 globotriaosylceramide are increased in patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.4[Matreya, LLC. Catalog No. 1551]


1.Lingwood, C.A., and Branch, D.R.The role of glycosphingolipids in HIV/AIDSDiscov. Med.11(59)303-313(2011) 2.Hoffmann, P., HÜlsewig, M., Duvar, S., et al.On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometryRapid Commun. Mass. Spectrom.24(15)2295-2304(2010) 3.Feldt-Rasmussen, U., Rasmussen, A.K., Mersebach, H., et al.Fabry disease: A new challenge in endocrinology and metabolism•Eur. J. Endocrinol.146(6)741-742(2002) 4.Hou, Y., Li, J., Xie, H., et al.Differential plasma lipids profiling and lipid signatures as biomarkers in the early diagnosis of ovarian carcinoma using UPLC-MSMetabolomics12(18)(2015)

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024